{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:19:17Z","timestamp":1778660357061,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clml.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:16:37Z","timestamp":1674702997000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine\u00a0+\u00a0Rituximab in Low-grade Lymphomas"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijan J.","family":"Borah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchita","family":"Dholakia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-985X","authenticated-orcid":false,"given":"Liuyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5726-0853","authenticated-orcid":false,"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-094X","authenticated-orcid":false,"given":"Han W","family":"Tun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2023.01.010_bib0001","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA: A Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clml.2023.01.010_bib0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/annonc\/mdn668","article-title":"Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy","volume":"20","author":"Gobbi","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.010_bib0003","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2013.11.225","article-title":"Radiation therapy administration and survival in stage I\/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"88","author":"Olszewski","year":"2014","journal-title":"Int J Radiat Oncol, Biology Phys"},{"issue":"1","key":"10.1016\/j.clml.2023.01.010_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2023.01.010_bib0005","first-page":"148","article-title":"Treatment patterns and health care costs in commercially insured patients with follicular lymphoma","volume":"7","author":"Fowler","year":"2020","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.clml.2023.01.010_bib0006","series-title":"CD20-Targeted Systemic Radio-Immunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Low Grade Non-Hodgkin Lymphomas [M.S.]","author":"Alhaj Moustafa","year":"2021"},{"issue":"10 Suppl","key":"10.1016\/j.clml.2023.01.010_bib0007","first-page":"3281s","article-title":"Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody","volume":"5","author":"Wiseman","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2023.01.010_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-8140(92)90342-R","article-title":"Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation","volume":"23","author":"Knox","year":"1992","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.01.010_bib0009","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12695","article-title":"Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study","volume":"164","author":"Ibatici","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.010_bib0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.01.010_bib0011","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3109\/10428194.2014.975801","article-title":"Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma","volume":"56","author":"Lossos","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2023.01.010_bib0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","author":"Samaniego","year":"2014","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2023.01.010_bib0013","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2019-130384","article-title":"Long-term outcome of patients with marginal zone non-hodgkin lymphoma (MZL) treated with Yttrium-90 Ibritumomab Tiuxetan: the Mayo clinic experience","volume":"134","author":"Alhaj Moustafa","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2023.01.010_bib0014","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2019-129391","article-title":"Long-term outcome of patients with low-grade follicular lymphoma treated with Yttrium-90 Ibritumomab Tiuxetan: the Mayo clinic experience","volume":"134","author":"Alhaj Moustafa","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.01.010_bib0015","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clml.2022.03.004","article-title":"Real world long-term follow-up experience with Yttrium-90 ibritumomab tiuxetan in previously untreated patients with low-grade follicular lymphoma and marginal zone lymphoma","volume":"22","author":"Alhaj Moustafa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.01.010_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clml.2023.01.010_bib0017","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clml.2023.01.010_bib0018","unstructured":"US Department of Health and Human Services: Common Terminology Criteria for Adverse Events. Version 5.0."},{"issue":"11","key":"10.1016\/j.clml.2023.01.010_bib0019","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood.V106.11.2436.2436","article-title":"Cost-effectiveness of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma","volume":"106","author":"Thompson","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.01.010_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:31Z","timestamp":1761871291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2152265023000289"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine\u00a0+\u00a0Rituximab in Low-grade Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}